CSPC Pharmaceutical Group Limited
CHJTFOTCHealthcare● Active
$1.05
+$0.00(+0.00%)
Market Cap$12.0B
P/E Ratio—
52W High$1.39
52W Low$0.54
CSPC Pharmaceutical Group Limited (CHJTF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CHJTF · earnings · updated Jun 8, 2026
Latest Earnings
Q3 FY2025Report Date: Aug 22, 2025EPS Actual
$0.03
Revenue
$1.85B
Est. $1.03B · +79.3%
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Aug 22, 2025
After Market Close
▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
CHJTF reports quarterly as a OTC-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 26, 2026 | $0.04 | — | — | — | $1.14B | — |
| ◌ Q3 FY2026 | Aug 26, 2026 | $0.03 | — | — | — | $2.33B | — |
| — Q3 FY2025 | Aug 22, 2025 | — | $0.03 | — | $1.85B | $1.03B | +79.3% |
| — Q2 FY2025 | May 29, 2025 | — | $0.02 | — | $1.88B | $1.03B | +82.2% |
| — Q4 FY2024 | Nov 15, 2024 | — | $0.03 | — | $2.08B | — | — |
| — Q2 FY2024 | May 27, 2024 | — | $0.01 | — | $0.97B | — | — |
| — Q2 FY2023 | Jun 30, 2023 | — | $0.02 | — | $1.02B | — | — |
| ▲ Q1 FY2023 | Mar 22, 2023 | $0.12 | $0.14 | +16.7% | $1.94B | $2.31B | -16.1% |
Q3 FY2026
Aug 26, 2026
EPS Actual
—
EPS Est.
$0.04
EPS Surpr.
—
Revenue
—
Q3 FY2026
Aug 26, 2026
EPS Actual
—
EPS Est.
$0.03
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 22, 2025
EPS Actual
$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
$1.85B
Q2 FY2025
May 29, 2025
EPS Actual
$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$1.88B
Q4 FY2024
Nov 15, 2024
EPS Actual
$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
$2.08B
Q2 FY2024
May 27, 2024
EPS Actual
$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.97B
Q2 FY2023
Jun 30, 2023
EPS Actual
$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$1.02B
Q1 FY2023
Mar 22, 2023Beat
EPS Actual
$0.14
EPS Est.
$0.12
EPS Surpr.
+16.7%
Revenue
$1.94B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.28 | $0.28 | $0.28 | 1 |
| Q3 FY2026 | $0.22 | $0.28 | $0.34 | 1 |
| Q2 FY2026 | $0.27 | $0.27 | $0.27 | 1 |
| Q1 FY2026 | $0.22 | $0.28 | $0.34 | 1 |
| Q4 FY2025 | $0.28 | $0.28 | $0.28 | 1 |
| Q3 FY2025 | $0.22 | $0.28 | $0.34 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $18.1B | $18.1B | $18.1B | 1 |
| Q3 FY2026 | $15.1B | $18.1B | $21.0B | 1 |
| Q2 FY2026 | $18.3B | $18.3B | $18.3B | 1 |
| Q1 FY2026 | $16.2B | $18.1B | $20.0B | 2 |
| Q4 FY2025 | $17.0B | $18.1B | $19.2B | 2 |
| Q3 FY2025 | $16.4B | $17.7B | $18.7B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q3 FY2025 | Aug 22, 2025 | — | $1.27 | $1.27 | +0.00% |
| — Q2 FY2025 | May 29, 2025 | — | $0.81 | $0.81 | +0.00% |
| — Q4 FY2024 | Nov 15, 2024 | — | $0.83 | $0.83 | +0.00% |
| — Q2 FY2024 | May 27, 2024 | — | $0.84 | $0.84 | +0.00% |
| — Q2 FY2023 | Jun 30, 2023 | — | $0.83 | $0.83 | +0.00% |
| ▲ Q1 FY2023 | Mar 22, 2023 | +16.7% | $1.13 | $1.07 | -5.31% |
| ▲ Q4 FY2022 | Nov 22, 2022 | +8.3% | $0.99 | $0.99 | +0.00% |
| ▼ Q2 FY2022 | May 25, 2022 | -25.0% | $1.02 | $1.03 | +0.98% |
Q3 FY2025+0.00%
Report Date
Aug 22, 2025
EPS Beat/Miss
—
Price Before
$1.27
Price After
$1.27
Q2 FY2025+0.00%
Report Date
May 29, 2025
EPS Beat/Miss
—
Price Before
$0.81
Price After
$0.81
Q4 FY2024+0.00%
Report Date
Nov 15, 2024
EPS Beat/Miss
—
Price Before
$0.83
Price After
$0.83
Q2 FY2024+0.00%
Report Date
May 27, 2024
EPS Beat/Miss
—
Price Before
$0.84
Price After
$0.84
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$0.83
Price After
$0.83
Q1 FY2023-5.31%
Report Date
Mar 22, 2023
EPS Beat/Miss
+16.7%
Price Before
$1.13
Price After
$1.07
Q4 FY2022+0.00%
Report Date
Nov 22, 2022
EPS Beat/Miss
+8.3%
Price Before
$0.99
Price After
$0.99
Q2 FY2022+0.98%
Report Date
May 25, 2022
EPS Beat/Miss
-25.0%
Price Before
$1.02
Price After
$1.03
Avg Beat Reaction-2.65%
Avg Miss Reaction+0.98%
Beat Rate2 / 8 quarters
Largest Move-5.31% (Q1 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CHJTF ends December
CSPC Pharmaceutical Group Limited (CHJTF) most recently reported earnings on August 22, 2025 for Q3 FY2025, posting EPS of $0.03 (in line with the analyst consensus of —). CHJTF has beaten EPS estimates for 2 consecutive quarters. The next CHJTF earnings date is expected around September 1, 2026.
Each quarter, investors track CHJTF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CHJTF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CHJTF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CHJTF earnings · 4 questionsCSPC Pharmaceutical Group Limited's next earnings report is expected around September 1, 2026. CHJTF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CHJTF historically reports after market close (AMC).
CHJTF earnings datewhen is CHJTF earningsCHJTF next earnings datewhen does CHJTF report earningsCHJTF earnings calendar
▸ Source: FMP · CSPC Pharmaceutical Group Limited SEC filings · US GAAP · CSPC Pharmaceutical Group Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026